Zealand Pharma: clinical trial for short bowel syndrome.
(CercleFinance.com) - Zealand Pharma has initiated a clinical trial to evaluate the potential of glepaglutide for the treatment of short bowel syndrome (SBS).
30 patients have already been dosed with glepaglutide in this clinical trial, which was started after positive Phase 2 results reported in June 2017 in patients with short bowel syndrome.
Results from the trial are due in the first quarter of 2018.
Short bowel syndrome involves intestinal function failure following the surgical removal of large parts of the intestine due to diseases such as cancer and Crohn's disease.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
30 patients have already been dosed with glepaglutide in this clinical trial, which was started after positive Phase 2 results reported in June 2017 in patients with short bowel syndrome.
Results from the trial are due in the first quarter of 2018.
Short bowel syndrome involves intestinal function failure following the surgical removal of large parts of the intestine due to diseases such as cancer and Crohn's disease.
Copyright (c) 2017 CercleFinance.com. All rights reserved.